About Array BioPharma (ARRY)

Array BioPharma Inc (ARRY) is a biopharmaceutical company that specializes in the discovery, development, and commercialization of targeted small molecule drugs to treat patients with cancer and other diseases. The company's portfolio includes several clinical-stage drug candidates that are being evaluated for a variety of indications, including solid tumors, hematologic malignancies, and rare diseases. Array BioPharma's approach to drug development is based on a deep understanding of the underlying biology of disease and the identification of specific molecular targets that can be modulated by small molecules. By focusing on these targets, the company aims to develop drugs that have the potential to be more effective and less toxic than traditional therapies.

One of Array BioPharma's most promising drug candidates is a BRAF inhibitor called encorafenib, which is being developed in combination with a MEK inhibitor called binimetinib for the treatment of patients with BRAF-mutant melanoma. Preliminary data from a phase 3 clinical trial showed that the combination therapy significantly improved progression-free survival compared to standard treatment with a BRAF inhibitor alone. Array BioPharma plans to submit a New Drug Application to the U.S. Food and Drug Administration for encorafenib and binimetinib in the near future. The company is also exploring the potential of its drug candidates in other indications, such as colorectal cancer and non-small cell lung cancer.